Remdesivir treatment for patients with moderate to severe COVID-19

Date
2022
Author
ÜNAL, SERHAT
Erdinc, Sebnem
Tabak, Fehmi
Gül, Ahmet
Alp, Emine
Sevgi, Dilek Yildiz
Cagatay, Arif Atahan
Bozkurt, Ilkay
Yasar, Kadriye Kart
Senoglu, Sevtap
HASANOĞLU, İMRAN
Guner, Rahmet
Celik, Ilhami
KANAT, FİKRET
Batirel, Ayse
TELLİ DİZMAN, GÜLÇİN
Eren, Esma
KAZAK, ESRA
KARAALİ, RIDVAN
Celikbas, Aysel
PULLUKÇU, HÜSNÜ
Metadata
Show full item record
Abstract
Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.
URI
http://hdl.handle.net/20.500.12627/188135
https://avesis.istanbul.edu.tr/api/publication/3d334c46-090c-4756-831a-41c821b37654/file
https://doi.org/10.55730/1300-0144.5387
Collections